Neuralink anticipates securing approval for its groundbreaking 'Telepathy' brain-computer interface device by 2029, with ambitions to perform 2,000 surgeries annually, generating a revenue of $100 million. By 2030, the company plans to unveil its 'Blindsight' device, scaling up the number of surgeries to 10,000 annually and projecting revenues to surpass $500 million.